Effect of Different Sedation and Analgesia Strategies on Patients With Mechanical Ventilation

NCT ID: NCT05024799

Last Updated: 2021-08-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

300 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-01-31

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Most patients in ICU are treated with a combination of analgesics and sedatives in most cases. Due to the different mechanism of different sedative and analgesic drugs, different antagonistic or synergistic effects may occur when combined with drugs, resulting in different clinical effects, especially significant effects on ventilators for patients with assisted breathing. Therefore, this study hopes to compare the effects of different sedative and analgesic drug combinations on the duration of mechanical ventilation for patients with ventilators, so as to guide the clinical adoption of a more reasonable sedative and analgesic scheme.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Respiratory Insufficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

F-P group

the combination of fentanyl and propofol

Group Type EXPERIMENTAL

Fentanyl, propofol

Intervention Type DRUG

The patients in this group will be administered with fentanyl and propofol

F-D group

the combination of fentanyl and dexmedetomidine

Group Type EXPERIMENTAL

fentanyl and dexmedetomindine

Intervention Type DRUG

The patients in this group will be administered with fentanyl and dexmedetomindine

B-P group

the combination of butorphanol and propofol

Group Type EXPERIMENTAL

Butorphanol and propofol

Intervention Type DRUG

The patients in this group will be administered with butorphanol and propofol

B-D group

the combination of butorphanol and dexmedetomidine

Group Type EXPERIMENTAL

Butorphanol and dexmedetomindine

Intervention Type DRUG

The patients in this group will be administered with butorphanol and dexmedetomindine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fentanyl, propofol

The patients in this group will be administered with fentanyl and propofol

Intervention Type DRUG

fentanyl and dexmedetomindine

The patients in this group will be administered with fentanyl and dexmedetomindine

Intervention Type DRUG

Butorphanol and propofol

The patients in this group will be administered with butorphanol and propofol

Intervention Type DRUG

Butorphanol and dexmedetomindine

The patients in this group will be administered with butorphanol and dexmedetomindine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults who are treated with sedation and analgesia for invasive mechanical ventilation
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The Affiliated Hospital of Qingdao University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

JinyanXing

Director

Responsibility Role PRINCIPAL_INVESTIGATOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jinyan Xing, Dr

Role: CONTACT

86-0532-82919386 ext. 82919386

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

QYFYKYLL931311920

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.